Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Environmental impact of pharmaceuticals and personal care products wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Prescription costs wikipedia , lookup
Electronic prescribing wikipedia , lookup
Theralizumab wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Adherence (medicine) wikipedia , lookup
National Institute for Health and Care Excellence wikipedia , lookup
Royal Wolverhampton NHS Trust Wolverhampton City Clinical Commissioning Group Wolverhampton Shared Care Agreement Leflunomide (Arava®) - Hospital monitored ESCA: For the treatment of rheumatological conditions SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient’s Name: NHS Number: Date of Birth: Date Treatment Started: (Add Date) One copy of information leaflet given to patient One copy of agreement sent to general practitioner One copy filed in patients notes Name of Initiating Doctor: Consultant: Speciality: Fax Number: 01902 695736 PRIMARY CARE SECTION TO BE COMPLETED BY GENERAL PRACTITIONER I agree*/don’t agree* to enter into a shared care arrangement for the treatment of the above patient with this medicine (*delete as appropriate) GP Name: Signature: Date: Once signed please detach this sheet and fax to the number shown above. File copy in patient’s record and add read code 66S2 or XaK6z depending on GP clinical system. BACK-UP ADVICE AND SUPPORT Contact details Telephone No. Rheumatology Nurse Helpline 01902 695491 01902 695492 01902 695495 Rheumatology Secretaries Hospital Pharmacy Department Mrs S. Reed 01902 695136 Email address: [email protected] This Shared Care Agreement should be read in conjunction with the Summary of Product Characteristics (SPC) for leflunomide Date approved: May 2013 Expiry date: 31/12/2017 Royal Wolverhampton NHS Trust Wolverhampton City Clinical Commissioning Group Wolverhampton Shared Care Agreement Leflunomide (Arava®) - Hospital monitored ESCA: For the treatment of rheumatological conditions Patient’s Name: Date treatment commenced: AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This shared care agreement outlines suggested ways in which the responsibilities for managing the prescribing of leflunomide can be shared between the specialist and general practitioner (GP). GPs are invited to participate. If GPs are not confident to undertake these roles, then they are under no obligation to do so. In such an event, the total clinical responsibility for the patient for the diagnosed condition remains with the specialist. If a specialist asks the GP to prescribe this drug, the GP should reply to this request as soon as practicable. Sharing of care assumes communication between the specialist, GP and patient. The intention to share care should be explained to the patient by the doctor initiating treatment. It is important that patients are consulted about treatment and are in agreement with it. The doctor who prescribes the medication legally assumes clinical responsibility for the drug and the consequences of its use. RESPONSIBILITIES and ROLES Specialist responsibilities Diagnosis and initiation of leflunomide treatment. Discuss the benefits and side effects of treatment with the patient. Ask the GP whether he or she is willing to participate in shared care, and agree with the GP as to who will discuss the shared care arrangement with the patient. 4. Dose stabilisation: initial dosage adjustment until stable. Thereafter, during maintenance treatment, advice to the GP on any further dose adjustments required. 5. Monitor FBC and LFT every 2 weeks for six months until stable and then every two months thereafter. If coprescribed with another immunosuppressant or potential hepatotoxic agent blood checks should continue long term, at least once a month. If ALT/AST 2-3x upper limit normal – reduce dose to 10mg, recheck weekly. If normalised – continue 10mg; if remains elevated withdraw drug and discuss with specialist team. If ALT/AST greater than 3 x normal, stop drug, recheck within 72 hours. If still greater than 3 times normal withdraw drug and consider washout 6. BP should be checked each visit. If BP greater than 140/90 treat in line with NICE guidance. If BP remains uncontrolled stop leflunomide and consider washout. 7. Weight should be checked at each visit. If more than 10% weight loss with no other cause identified, reduce dose or stop and consider washout. 8. Communicate promptly with the GP when treatment is changed. 9. Have a mechanism in place to receive rapid referral of a patient from the GP in the event of deteriorating clinical condition. 10. Advise the GP on stopping treatment (if appropriate). 11. Report serious adverse events to the MHRA 12. Ensure that clear backup arrangements exist for GPs to obtain advice and support. General Practitioner responsibilities 1. Reply to the request for shared care as soon as practicable. 2. Prescribe leflunomide at the dose recommended. 3. Adjust the dose as advised by the specialist. 4. Report to and seek advice from the specialist on any aspect of patient care that is of concern and may affect treatment. 5. Refer patient to the specialist if his or her condition deteriorates. 6. Stop treatment on the advice of the specialist or immediately if an urgent need to stop treatment arises. 7. Report adverse events to the specialist and MHRA. Patient's role 1. Report to the specialist or GP if he or she does not have a clear understanding of the treatment. 2. Share any concerns in relation to treatment with leflunomide 3. Report any adverse effects to the specialist or GP whilst taking leflunomide 1. 2. 3. This Shared Care Agreement should be read in conjunction with the Summary of Product Characteristics (SPC) for leflunomide Date approved: May 2013 Expiry date: 31/12/2017 Royal Wolverhampton NHS Trust Wolverhampton City Clinical Commissioning Group Wolverhampton Shared Care Agreement Leflunomide (Arava®) - Hospital monitored ESCA: For the treatment of rheumatological conditions SUPPORTING CLINICAL INFORMATION Indications Leflunomide is licensed for the treatment of adult patients with active rheumatoid arthritis (RA) as a diseasemodifying anti-rheumatic drug (DMARD) and for the treatment of active psoriatic arthritis (PsA). Dosage and Administration The maintenance dose is 10 to 20 mg/day for RA and 20 mg/day for PsA. A washout period should be followed when switching to another hepato- or haematotoxic drug, or in cases of acute leflunomide toxicity (see the [SPC] for more details). Contraindications Leflunomide must not be used in patients with Stevens-Johnson syndrome, toxic epidermal necrolysis or erythema multiforme. Leflunomide is also contraindicated in patients with impaired immune, liver or bone marrow function; serious infections, or severe hypoproteinaemia. See the SPC for further details. Side Effects The most common adverse events with leflunomide treatment in clinical trials were gastrointestinal effects, pruritus, rash, hypertension, alopecia and liver enzyme elevations. Postmarketing, there have been rare reports of serious hepatic reactions and pancytopenia. See the SPC for more details on adverse events. Monitoring Monitoring of ALT (SGPT) and a full blood count including differential white blood cell count and a platelet count must be performed before initiation of leflunomide, every 2 weeks during the first 6 months of treatment, and then every 8 weeks thereafter. If ALT (SGPT) elevations of 2- to 3-fold the upper limit of normal occur then the dose can be reduced from 20 mg to 10 mg and monitoring must be performed weekly. If ALT elevations of more than 2-fold the upper limit persist, or more than 3-fold the upper limit of normal are present, leflunomide treatment must be discontinued and wash-out procedures initiated. The SPC recommends that monitoring of liver enzymes be continued after discontinuation of treatment until liver enzyme levels have normalised. Drug Interactions Recent treatment with hepatotoxic or haematotoxic drugs may result in increased side effects; care should be taken when initiating leflunomide therapy. The British Society for Rheumatology guideline advises a maximum of 10mg/day if used concomitantly with another potentially hepatotoxic DMARD such as methotrexate. Switching to another DMARD after leflunomide treatment may raise the possibility of additive risks because of its long half-life. A washout period is required. Patients treated with leflunomide should not receive concomitant treatment with cholestyramine or activated powdered charcoal, because this leads to rapid and significant decreases in plasma leflunomide concentration. Vaccination The use of LIVE vaccine is not recommended during drug treatment with immunosuppressant drugs. Acknowledgements Refer to MTRAC VS 04/15. Version Control Version Date of Issue Author/s Brief Description of Changes This Shared Care Agreement should be read in conjunction with the Summary of Product Characteristics (SPC) for leflunomide Date approved: May 2013 Expiry date: 31/12/2017 Royal Wolverhampton NHS Trust Wolverhampton City Clinical Commissioning Group Wolverhampton Shared Care Agreement Leflunomide (Arava®) - Hospital monitored ESCA: For the treatment of rheumatological conditions 1.0 1.1 10 June 2013 Uzoma Ibechukwu Under ‘specialist responsibilities’; Monitor FBC and LFT changed from ‘every month’ to ‘every 2 weeks’ 1.2 25/06/2013 R Eardley Removal of pharmacy fax numbers References 1. 2. 3. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. BSr/DMARD guideline group April 2008, update November 2009. Electronic Medicines Compendium. Summary of Product Characteristics: Leflunomide. Surrey: eMC 2012. Available from www.medicines.org.uk MTRAC guidance VS04/15. This Shared Care Agreement should be read in conjunction with the Summary of Product Characteristics (SPC) for leflunomide Date approved: May 2013 Expiry date: 31/12/2017